Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

'We're ready': Schiphol airport gears up for chilled vaccine cargos

Thu, 26th Nov 2020 13:29

* Air France-KLM has already shipped vaccines at -80C

* Schiphol is Europe's second largest pharmaceutical hub

* Air France-KLM adding extra cold storage at Schiphol

By Toby Sterling

SCHIPHOL AIRPORT, Netherlands, Nov 26 (Reuters) - In
cavernous cold-storage warehouses at Amsterdam's Schiphol
Airport, KLM workers are gearing up for a surge next year in
COVID-19 vaccine cargos that will need to be flown around the
world at ultra-low temperatures.

A major hub for pharmaceutical products, Schiphol has
already handled some of the vaccines being used in trials and
KLM's boss is confident its "cold chain" operations will cope
with the influx of cargos as mass inoculations start in earnest.

"The short and sweet of it is, yes, we're ready," KLM Chief
Executive Pieter Elbers told Reuters. "Obviously both for
societies and our industry it's of paramount importance to have
these vaccines distributed at the quickest possible pace."

While no COVID-19 vaccine has yet been approved by U.S. or
European regulators, the shot developed by Pfizer and
BioNTech is the most advanced in the process and could
be ready for rapid production and distribution next month.

But it needs to be stored and shipped at minus 70 degrees
Celsius while Moderna's candidate has to be kept at
-20C, at least until the drugs have reached their destinations
where they can survive in normal fridges for short periods.

Allowed behind strict security at Schiphol on Wednesday,
Reuters watched Air France-KLM staff prepare four
so-called active containers for a shipment of chilled
pharmaceuticals bound for Toronto in Canada.

Wearing thick blue gloves, workers topped up dry ice in
other active containers, which also have a battery-powered
electrical refrigeration system and an array of sensors to
ensure products stay within their target range, as low as -20C.

"Schiphol will, for sure, be one of the major airports for
the vaccines," said Marcel Kuijn, global head of pharmaceutical
logistics for Air France-KLM Cargo.

"Our market share on the routes we fly is 10% to 20%, that's
in our regular pharma business, so we expect to get at least
that part of the vaccine distribution," he told Reuters.

COOL BOXES

Pfizer's vaccine is transported at -80C in small cool boxes
holding about 5,000 doses which must be kept packed in dry ice
until shortly before use. Moderna's candidate is suitable for
the larger "active" containers which can take 30,000 doses.

The vaccine being developed by AstraZeneca and
Oxford University is stable at normal fridge temperatures of 2C
to 8C so it has more transport options.

Kuijn estimated that while vaccines will begin and end their
journeys in refrigerated trucks, at least 30% will be flown to
their destinations.

Schiphol is the second biggest hub for pharmaceutical
products in Europe after Frankfurt so it is expected to be both
a staging ground for vaccines from India, Italy or the United
States, and a departure point for vaccines made in Europe.

Some other vaccines being developed in China are also stable
in normal fridges and Kuijn reckons only a minority COVID-19
shots will need to be transported frozen.

Air France-KLM currently operates 537 flights a week to
about 100 destination in Asia, the Middle East, Africa and the
Americas. It is likely that Franco-Dutch airline will be a major
carrier to African countries, given its network.

Kuijn said bottlenecks at Schiphol were unlikely, and while
containers would be in high demand, he did not expect shortages
as different vaccines will come available at different times.

"The first ones will probably come in December, January, and
from there on new vaccines will be approved," he said.

The KLM Cargo warehouse at Schiphol has four cold storage
areas for pharmaceuticals and a fifth will be ready in January.

"The bigger containers can carry up to 30,000 doses of the
vaccine," said Paul Crombach, program manager of KLM's "cool
chain" programme and the head of the team preparing for the mass
transport of COVID-19 vaccines.

"We knew we're going to have to transport a lot of the
vaccine ... but we have space as you can see," he said,
gesturing to the vast warehouse behind him decked out with
conveyor belts and robotic lifting arms.
(Reporting by Toby Sterling; Editing by David Clarke)

More News
9 May 2023 14:28

Director dealings: AstraZeneca CFO makes $1.5m sale, IHG chair buys in

(Sharecast News) - At the top of the list of FTSE 350 director sells on Tuesday was AstraZeneca, whose chief financial officer sold almost $1.5m worth of the company's American depositary shares.

Read more
9 May 2023 09:29

LONDON BROKER RATINGS: RBC raises Intertek; Davy likes Greencoat UK

(Alliance News) - The following London-listed shares received analyst recommendations xxxxday morning:

Read more
9 May 2023 09:09

TOP NEWS: AstraZeneca's Farxiga approved in US to treat heart failure

(Alliance News) - AstraZeneca PLC on Tuesday said its Farxiga drug has been approved by the US Food & Drug Administration to reduce the risk of cardiovascular death and hospitalisation for heart failure in adults.

Read more
9 May 2023 07:16

AstraZeneca's Farxiga heart failure drug gets extended US approval

(Sharecast News) - AstraZeneca's Farxiga drug has been approved in the US to reduce the risk of cardiovascular death, hospitalisation for heart failure and urgent heart failure visits in adults, the company said on Tuesday.

Read more
2 May 2023 14:28

IN BRIEF: AstraZeneca Chair Michel Demare buys GBP230,000 in shares

AstraZeneca PLC - Cambridge, England-based biopharmaceutical maker - Non-Executive Chair Michel Demare buys 2,000 shares at GBP117.01, worth GBP234,020, on Friday last week.

Read more
2 May 2023 12:15

Director dealings: Genus announces new CEO's compensation, AstraZeneca chair spends £0.23m

(Sharecast News) - Livestock genetics company Genus saw its shares weaken on Tuesday afternoon after it announced the agreed reward arrangements for its incoming CEO, Jorgen Kokke.

Read more
2 May 2023 09:06

AstraZeneca bemoans ODAC judgement on use of Lynparza drug for cancer

(Alliance News) - AstraZeneca PLC on Tuesday bemoaned the results of a regulatory meeting held by the US Food & Drug Administration, which suggested its Lynparza prostate cancer treatment should be limited to tumours with a BRCA mutation.

Read more
2 May 2023 08:51

AstraZeneca 'disappointed' with FDA panel vote on prostate drug

(Sharecast News) - AstraZeneca said it was disappointed with a decision by a panel of US Food and Drug Administration advisers to restrict use of its treatment for a type of prostate cancer.

Read more
1 May 2023 12:35

AstraZeneca "disappointed" with US ODAC's guidance on Lynparza

(Alliance News) - AstraZeneca PLC on Friday said the US Food & Drug Administration's Oncologic Drugs Advisory Committee has recognised a favourable benefit risk profile for its Lynparza, plus abiraterone and prednisone or prednisolone, for the treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Read more
29 Apr 2023 15:45

US FDA panel backs restricted use of AstraZeneca's prostate cancer drug

April 28 (Reuters) - A panel of U.S. Food and Drug Administration advisers on Friday voted for the restricted use of British drugmaker AztraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer.

Read more
29 Apr 2023 15:45

US FDA panel backs AstraZeneca's prostate cancer drug

April 28 (Reuters) - A panel of U.S. Food and Drug Administration advisers on Friday voted for the expanded use of British drugmaker AztraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer.

Read more
27 Apr 2023 23:14

Drugmakers scout for deals, ramp up research spending

April 27 (Reuters) - Drugmakers including Merck & Co , AstraZeneca Plc and AbbVie Inc said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.

Read more
27 Apr 2023 18:38

FTSE 100 closes lower for fourth day; Barclays shines

Unilever climbs on upbeat Q1 sales

*

Read more
27 Apr 2023 17:17

Drugmakers scout for deals, ramp up research spending

April 27 (Reuters) - Drugmakers including Merck & Co , AstraZeneca Plc and AbbVie Inc said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.

Read more
27 Apr 2023 12:36

AstraZeneca increases bets on China as COVID vaccine sales fade

AstraZeneca already biggest drugmaker in China

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.